Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: J Neurochem. 2009 Jun 15;110(4):1226–1240. doi: 10.1111/j.1471-4159.2009.06212.x

Fig. 5. BDNF immunoreactivity was markedly down-regulated in the vehicle-treated group, but up-regulated in SB- or TSA-treated rats in the ipsilateral SVZ, aSVZ, and frontal cortex on Day 7 after pMCAO.

Fig. 5

SB-induced BDNF up-regulation in the aSVZ and frontal cortex was blocked by co-treatment with K252a.

(A) (a) Sham, (b) vehicle, (c) SB, (d) TSA. BDNF (green). Scale bar = 50 µm. Results are from representative brain sections (n = 3–4 per group).

(B) (a) Sham, (b) vehicle, (c) SB, (d) K252a + SB, (e) K252a. BDNF (green). Scale bar = 50 µm.

(C) (a) Sham, (b) vehicle, (c) SB, (d) K252a + SB, (e) K252a. BDNF (green). Scale bar = 50 µm. Experimental conditions are described in the Methods. SVZ: subventricular zone, LV: lateral ventricle, aSVZ: anterior subventricular zone, Fcx: frontal cortex.

(D), (E) & (F) Quantified results of BDNF (+) cells in the SVZ, aSVZ and frontal cortex under the experimental conditions shown in (A)–(C). Data are mean ± SEM and were analyzed from 4 rats per group, **p< 0.01, ***p< 0.001, between indicated groups.